These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36795508)

  • 21. Application of PCSK9 Inhibitors in Practice.
    Kaufman TM; Warden BA; Minnier J; Miles JR; Duell PB; Purnell JQ; Wojcik C; Fazio S; Shapiro MD
    Circ Res; 2019 Jan; 124(1):32-37. PubMed ID: 30605414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitor Prescriptions for Secondary Prevention of Clinical Atherosclerotic Cardiovascular Disease.
    Blumenthal DM; Maddox TM; Aragam K; Sacks CA; Virani SS; Wasfy JH
    Circ Cardiovasc Qual Outcomes; 2021 Sep; 14(9):e007237. PubMed ID: 34404223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
    Gallego-Colon E; Daum A; Yosefy C
    Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans.
    Derington CG; Colantonio LD; Herrick JS; Cook J; King JB; Rosenson RS; Poudel B; Monda KL; Navar AM; Mues KE; Stevens VW; Nelson RE; Vanneman ME; Muntner P; Bress AP
    J Am Heart Assoc; 2021 Apr; 10(8):e019254. PubMed ID: 33821686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction.
    Lou B; Liu H; Luo Y; Jiang GT; Wu H; Wang C; Wu Y; Zhou B; Yuan Z; She J; Liu J
    Lipids Health Dis; 2022 Oct; 21(1):105. PubMed ID: 36280861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipid Testing, Lipid-Modifying Therapy, and PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Eligibility in 27 979 Patients With Incident Acute Coronary Syndrome.
    Sarak B; Savu A; Kaul P; McAlister FA; Welsh RC; Yan AT; Goodman SG
    Circ Cardiovasc Qual Outcomes; 2021 Apr; 14(4):e006646. PubMed ID: 33813856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel Insights into the Management of Patients with Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: Baseline Findings from the PERI-DYS Study.
    Laufs U; Birkenfeld AL; Fraass U; Hohenstein B; Siegert C; Klotsche J; Steinhagen-Thiessen E; Pittrow D; Dexl S; Salmen S; Schettler VJJ; Parhofer KG;
    Cardiovasc Drugs Ther; 2024 Feb; 38(1):119-129. PubMed ID: 36178485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PCSK9 inhibitors in clinical practice: Novel directions and new experiences.
    Rallidis LS; Skoumas I; Liberopoulos EN; Vlachopoulos C; Kiouri E; Koutagiar I; Anastasiou G; Kosmas N; Elisaf MS; Tousoulis D; Iliodromitis E
    Hellenic J Cardiol; 2020; 61(4):241-245. PubMed ID: 31783124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation.
    LaFratte C; Peasah SK; Huang Y; Hall D; Patel U; Good CB
    J Am Heart Assoc; 2023 Sep; 12(18):e029707. PubMed ID: 37702065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.
    Rubino J; MacDougall DE; Sterling LR; Kelly SE; McKenney JM; Lalwani ND
    J Clin Lipidol; 2021; 15(4):593-601. PubMed ID: 34172394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors associated with time to initiation of a PCSK9 inhibitor after hospital discharge for acute myocardial infarction.
    McKinley EC; Bittner VA; Brown TM; Chen L; Colantonio LD; Exter J; Orroth KK; Reading SR; Rosenson RS; Muntner P
    J Clin Lipidol; 2022; 16(1):75-82. PubMed ID: 34848176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of Secondary Prevention Patients Eligible for PCSK9 Inhibitors Therapy According to the Routine Clinical Practice in Spain.
    Cosin-Sales J; Sidelnikov E; Villamayor S; Fernández M; Merino-Montero S; Zamora A
    Adv Ther; 2023 Jun; 40(6):2710-2724. PubMed ID: 36525203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia.
    Karalis DG; Mallya UG; Ghannam AF; Elassal J; Gupta R; Boklage SH
    Am J Cardiol; 2018 May; 121(10):1155-1161. PubMed ID: 29548678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with acute coronary syndrome: A systematic review meta-analysis.
    Nagendra L; Mahajan K; Gupta G; Dutta D
    Indian Heart J; 2023; 75(6):416-422. PubMed ID: 37777180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study.
    Alonso R; Arroyo-Olivares R; Muñiz-Grijalvo O; Díaz-Díaz JL; Muñoz-Torrero JS; Romero MJ; de Andrés R; Zambón D; Mañas MD; Fuentes-Jiménez F; Aguado R; Alvarez-Baños P; Arrieta F; Gonzalez-Bustos P; Cepeda J; Martin-Ordiales M; Mosquera D; Michan A; de Isla LP; Argueso R; Mata P
    Eur J Prev Cardiol; 2023 Mar; 30(4):320-328. PubMed ID: 36416136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Preoperative Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor on Carotid Artery Stenting.
    Shingai Y; Kimura N; Doijiri R; Takahashi K; Yokosawa M; Kanoke A; Kikuchi T; Sugawara T; Tominaga T
    World Neurosurg; 2020 Mar; 135():e36-e42. PubMed ID: 31655235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
    Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL;
    J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipid-lowering therapy with PCSK9-inhibitors in the real-world setting: Two-year experience of a regional lipid clinic.
    Zafrir B; Jubran A
    Cardiovasc Ther; 2018 Oct; 36(5):e12439. PubMed ID: 29863817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perceptions and Barriers on the Use of Proprotein Subtilisin/Kexin Type 9 Inhibitors in Heterozygous Familial Hypercholesterolemia (From a Survey of Primary Care Physicians and Cardiologists).
    Wong ND; Bang M; Block RC; Peterson ALH; Karalis DG
    Am J Cardiol; 2021 Aug; 152():57-62. PubMed ID: 34147211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness, Safety, and Adherence to Treatment of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Real Practice.
    Gayoso-Rey M; Díaz-Trastoy O; Romero-Ventosa EY; García-Beloso N; González-Freire L; Lorenzo-Lorenzo K; Mantiñán-Gil B; Palmeiro-Carballeira R; Bravo-Amaro M; López-Gil-Otero MDM; Martínez-Reglero C; Crespo-Diz C; Fernández-Catalina P; Piñeiro Corrales G
    Clin Ther; 2021 Apr; 43(4):e111-e121. PubMed ID: 33712271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.